Pasithea Therapeutics Corp. (KTTA) - 2025 Form 10-K Summary
Business Context and Reporting Period
Pasithea Therapeutics Corp. is a clinical-stage biotechnology company focused on developing treatments for RASopathies, MAPK pathway-driven tumors, and CNS disorders. The reporting period covers the fiscal year ended December 31, 2025. The Company is classified as an Emerging Growth Company and a Smaller Reporting Company. Its primary asset is the lead product candidate PAS-004, a next-generation macrocyclic MEK inhibitor.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(20.43) million | $(13.90) million |
| Operating Expenses | $20.86 million | $14.25 million |
| Cash and Cash Equivalents (Year-End) | $55.16 million | $6.92 million |
| Working Capital | $51.49 million | $6.25 million |
| Accumulated Deficit | $(70.01) million | $(49.58) million |
| Net Cash Used in Operating Activities | $(15.21) million | $(13.92) million |
| Net Cash Provided by Financing Activities | $63.52 million | $4.52 million |
Material Changes vs. Prior Period
- Capital Raise: The Company significantly improved its liquidity position through two major public offerings in May and December 2025, raising approximately $59.6 million in net proceeds, alongside $2.1 million from an ATM program and $2.2 million from warrant exercises.
- Expense Increase: General and Administrative (G&A) expenses increased by 82.6% to $12.88 million, primarily driven by a $4.16 million impairment charge related to the discontinuation of the PAS-003 program and increased personnel costs. Research and Development (R&D) expenses rose 10.9% to $7.98 million due to increased clinical trial and regulatory costs for PAS-004.
- Program Discontinuation: The Company ceased development of the PAS-003 program for ALS in 2025, resulting in the impairment of associated intangible assets and goodwill.
- Stock Structure: A 1-for-20 reverse stock split was effective in January 2024. In January 2026 (subsequent event), authorized shares were increased to 500 million.
Guidance, Outlook, and Risks
- Clinical Progress (PAS-004):
- Advanced Cancer Study: Dose escalation through cohort 8 (45 mg) is complete with no dose-limiting toxicities (DLTs). The trial is expected to conclude in 2028.
- NF1 Trial: The Phase 1/1b trial for adult NF1 patients initiated in May 2025. Part A is expected to complete by end of 2026, with Part B commencing in 2027.
- Liquidity Outlook: Management estimates that current cash resources ($55.2 million) are sufficient to fund operations through at least the first half of 2028. However, the Company expects to incur significant losses and will require additional capital to complete development and commercialization.
- Key Risks:
- Nasdaq Compliance: The Company received notice in February 2026 of non-compliance with the $1.00 minimum bid price requirement. It has 180 days to regain compliance, potentially via a reverse stock split.
- Manufacturing Dependence: Reliance on a single Chinese contract manufacturing organization (WuXi) exposes the Company to geopolitical risks and potential restrictions under the BIOSECURE Act.
- Profitability: The Company has no approved products and no revenue. It expects to continue incurring net losses for the foreseeable future.
Investor Verification Checklist
- Verify the status of the Nasdaq bid price compliance and any announced reverse stock split plans.
- Confirm the timeline and enrollment status of the Phase 1/1b Adult NF1 Trial and the FIH Phase 1 Advanced Cancer Study.
- Assess the impact of the BIOSECURE Act on the Company's relationship with its primary manufacturer, WuXi.
- Review the December 2025 Placement Agent Warrants liability valuation and potential dilution upon exercise.
- Monitor the cash burn rate relative to the projected runway into 2028 to determine the timing of future capital raises.